{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:16:27Z","timestamp":1787836587192,"version":"build-2784847793"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Benefits and risks of new therapies in Multiple Sclerosis (<jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content>) must be balanced carefully and tailored\u00a0to patients. We aimed to describe our experience with Fingolimod (<jats:styled-content style=\"fixed-case\">FTY<\/jats:styled-content>), correlating demographics, clinical and hematological features of the Relapsing<jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content>(<jats:styled-content style=\"fixed-case\">RMS<\/jats:styled-content>) cohort with the occurring Adverse Events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s).<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods<\/jats:title><jats:p>Pretreatment screening tests, cardiological observation, and safety follow\u2010up data were analyzed in 225<jats:styled-content style=\"fixed-case\">RMS<\/jats:styled-content>patients. Changes in continuous data were analyzed post hoc with Wilcoxon ranks test; categorical variables were examined using McNemar test. Two\u2010way repeated\u2010measures analysis of variance (<jats:styled-content style=\"fixed-case\">ANOVA<\/jats:styled-content>) was used to analyze differences between baseline characteristic of the cohorts and Liver Function Tests (<jats:styled-content style=\"fixed-case\">LFT<\/jats:styled-content>) alterations. Binary logistic regression models were used to identify which of the baseline factors influenced<jats:styled-content style=\"fixed-case\">LFT<\/jats:styled-content>alterations and the occurrence of infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During 2\u00a0years of follow\u2010up 24 patients (10%) interrupted<jats:styled-content style=\"fixed-case\">FTY<\/jats:styled-content>. Discontinuation most often was due to<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s (n\u00a0=\u00a014) or breakthrough disease (n\u00a0=\u00a05). The most frequently<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s were infections (10.6%). After the first year patients showing an infectious episode were mostly female (<jats:italic>p\u00a0<\/jats:italic>=\u00a0.04). The infections did not correlate with the decrease in white blood cells or to lymphocyte count.<jats:styled-content style=\"fixed-case\">AST<\/jats:styled-content>and<jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content>alterations \u200b\u200bwere observed mostly in males (<jats:italic>p\u00a0<\/jats:italic>=\u00a0.002 and<jats:italic>p\u00a0<\/jats:italic>=\u00a0.01, respectively), and increase in<jats:styled-content style=\"fixed-case\">GGT<\/jats:styled-content>\u200b\u200bwas reported in subjects older at<jats:styled-content style=\"fixed-case\">FTY<\/jats:styled-content>beginning (<jats:italic>p\u00a0<\/jats:italic>&lt;\u00a0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>For a patient\u2010centered safety monitoring of<jats:styled-content style=\"fixed-case\">FTY<\/jats:styled-content>, we may apply gender\u2010specific warnings, for the detection of transaminases abnormalities and infectious episodes.<\/jats:p><\/jats:sec>","DOI":"10.1002\/brb3.804","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T15:36:19Z","timestamp":1504020979000},"source":"Crossref","is-referenced-by-count":25,"title":["Gender differences in safety issues during Fingolimod therapy: Evidence from a real\u2010life Relapsing Multiple Sclerosis cohort"],"prefix":"10.1002","volume":"7","author":[{"given":"Alessia","family":"Manni","sequence":"first","affiliation":[{"name":"Department of Basic Medical Sciences, Neuroscience and Sense Organs University of Bari\u201d Aldo Moro\u201d Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita","family":"Direnzo","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neuroscience and Sense Organs University of Bari\u201d Aldo Moro\u201d Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Iaffaldano","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neuroscience and Sense Organs University of Bari\u201d Aldo Moro\u201d Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Di Lecce","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neuroscience and Sense Organs University of Bari\u201d Aldo Moro\u201d Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Tortorella","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neuroscience and Sense Organs University of Bari\u201d Aldo Moro\u201d Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Zoccolella","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neuroscience and Sense Organs University of Bari\u201d Aldo Moro\u201d Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Iaffaldano","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neuroscience and Sense Organs University of Bari\u201d Aldo Moro\u201d Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Trojano","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neuroscience and Sense Organs University of Bari\u201d Aldo Moro\u201d Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-1763","authenticated-orcid":false,"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neuroscience and Sense Organs University of Bari\u201d Aldo Moro\u201d Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.3065"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/315347"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr200273u"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.04.006"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.00130.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907839"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.08.005"},{"key":"e_1_2_6_10_1","unstructured":"European Medicines Agency (EMA). (2011).Assessment report: Gilenya. Doc Ref: EMA\/108602\/2011. Retrieved from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002202\/WC500104529.pdf. [Accessed Jun 29 2016]"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit376"},{"key":"e_1_2_6_12_1","first-page":"737","article-title":"The X\u2010files in immunity: Sex\u2010based differences predispose immune responses","volume":"8","author":"Fish E. N.","year":"2008","journal-title":"Nature Reviews"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513500551"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.035378"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.9.1022"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2014.03.002"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201200099"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005283464"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004274288"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-65"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000013"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068159"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.519"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31829a3311"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-016-2621-y"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1545"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pri.66"},{"key":"e_1_2_6_29_1","first-page":"1193","volume-title":"Handbook of parametric and nonparametric statistical procedures","author":"Sheskin D.","year":"2004"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.3390"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13849"},{"key":"e_1_2_6_32_1","unstructured":"US Food and Drug Administration (FDA)(2010).FDA approves first oral drug to reduce MS relapses[press release]. Retrieved fromhttp:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm226755.htm. [Accessed Jun 29 2016]"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1997.0230"},{"key":"e_1_2_6_34_1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0026-895X(25)10535-X","article-title":"Growth hormone regulation of male\u2010specific rat liver P450s 2A2 and 3A2: induction by intermittent growth hormone pulses in male but not female rats rendered growth hormone deficient by neonatal monosodium glutamate","volume":"48","author":"Waxman D. J.","year":"1995","journal-title":"Molecular Pharmacology"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200004271-00300"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbrb3.804","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:41:54Z","timestamp":1750830114000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1002\/brb3.804"],"URL":"https:\/\/doi.org\/10.1002\/brb3.804","archive":["Portico"],"relation":{},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]},"article-number":"e00804"}}